RxDoctor Payments DataLook up a doctor →

Sarah Land, DO

Psychiatry · Tulsa, OKNPI 1700956406

Payments from drug & device makers

$2,804,070in general payments, 2019–2025

Across 1,913 payments — averaging $1465.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.4M
  • Biogen$423K
  • Novo Nordisk AS$330K
  • AbbVie$327K
  • Boehringer Ingelheim$66K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$54K
  • plus $215K from 41 others
$21,973in research payments, 2019–2025

Across 18 payments — averaging $1220.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$14K
  • AbbVie$5K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$4K

What the payments were for

  • Consulting fees$12,2504%
  • Speaking & faculty fees$243,92985%
  • Travel & lodging$7,3043%
  • Food & beverage$23,5688%
  • Education$2510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,804,070 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$34,345
Medicare patients
108
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FanaptIloperidone11$31,796
TrintellixVortioxetine Hydrobromide39$23,952
VraylarCariprazine Hcl16$22,313
Chlorpromazine Hcl19$5,767
DayvigoLemborexant13$4,295
Clozapine76$4,094
Duloxetine Hcl74$3,452
Trazodone Hcl151$3,119
Aripiprazole52$2,903
Venlafaxine Hcl ErVenlafaxine Hcl67$2,084
Escitalopram Oxalate138$2,065
Desvenlafaxine Succinate ErDesvenlafaxine Succinate28$2,021
Lamotrigine70$1,414
Quetiapine Fumarate70$1,375
Lurasidone Hcl11$1,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Fanapt$1,253$31,79611 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$614$23,95239 claims
AbbVieVraylar$327,254$22,31316 claims
Eisai Inc.Dayvigo$380$4,29513 claims
Almatica Pharma LLCSertraline Hcl$27$1,08548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →